Casi Pharmaceuticals
Pharmaceuticals, 9620 Medical CTR Dr, Rockville, Maryland, 20850, United States, 51-200 Employees
Phone Number: 16*********
Who is CASI PHARMACEUTICALS
CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, U.S., and through...
Read More
-
Headquarters: 9620 Medical CTR Dr, Rockville, Maryland, 20850, United States
-
Employees: 51-200
-
Revenue: $1 Million to $5 Million
Industry: Pharmaceuticals
SIC Code: 2836
|
NAICS Code: 541715 |
Show More
Does something look wrong? Fix it. | View contact records from CASI PHARMACEUTICALS
CASI Pharmaceuticals Org Chart and Mapping
Email
Phone
Similar Companies to CASI Pharmaceuticals
Eikon Therapeutics
-
201-500
-
$ 10 Million to 25 Million
STATKING Clinical Services
-
11-50
-
$ 5 Million to 10 Million
thplasma
-
11-50
-
$ 1 Million to 5 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding CASI Pharmaceuticals
Answer: CASI Pharmaceuticals's headquarters are located at 9620 Medical CTR Dr, Rockville, Maryland, 20850, United States
Answer: CASI Pharmaceuticals's phone number is 16*********
Answer: CASI Pharmaceuticals's official website is https://casipharmaceuticals.com
Answer: CASI Pharmaceuticals's revenue is $1 Million to $5 Million
Answer: CASI Pharmaceuticals's SIC: 2836
Answer: CASI Pharmaceuticals's NAICS: 541715
Answer: CASI Pharmaceuticals has 51-200 employees
Answer: CASI Pharmaceuticals is in Pharmaceuticals
Answer: CASI Pharmaceuticals top competitors include: Eikon Therapeutics , STATKING Clinical Services , thplasma
Answer: CASI Pharmaceuticals contact info: Phone number: 16********* Website: https://casipharmaceuticals.com
Answer: CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China through which all of our China operations are conducted. CASI is dedicated to the development and delivery of high-quality pharmaceutical products and innovative therapeutics to patients worldwide while targeting the China market. We are focused on acquiring, licensing, developing and commercializing products that address areas of unmet medical need. We intend to become the leading platform to launch medicines in the greater China market leveraging our China-based regulatory and commercial competencies and our global drug development expertise. We have a strong and growing product pipeline of commercially available and clinical stage drug candidates, and will continue to (i) acquire additional approved and clinical stage drug candidates through in-license and acquisitions, and (ii) explore drug candidates in preclinical development. CASIs product portfolio includes (i) an autologous anti-CD19 T-cell therapy investigative product (CNCT19) being developed for the treatment of B-ALL and NHL (ii) CID-103, an anti-CD38 monoclonal antibody being developed for the treatment of certain hematological malignancies; (iii) China regional rights to three U.S. Food and Drug Administration (FDA)-approved drugs (EVOMELA (melphalan hydrochloride for injection) approved by Chinas National Medical Products Administration (NMPA) for marketing in China, ZEVALIN (ibritumomab tiuxetan) and MARQIBO (vincristine sulfate LIPOSOME injection) approved by NMPA for registration confirmatory trials in China; and (iv) a portfolio of FDA-approved abbreviated new drug applications (ANDAs).
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month